Shanghai fires 2 scientists after girl dies in world’s first brain gene-editing attempt

Shanghai’s municipal investigation team announced the dismissals in a statement on Friday, citing failures in safety reporting, clinical review and the disclosure of financial conflicts of interest, Shanghai Daily reported.

Both researchers were also barred for five years from state science and technology programs and from awards, and entered into a database of serious research integrity violations.

The South China Morning Post identified the two as Qiu Zilong, the project’s lead scientist at Shanghai Jiao Tong University, and his hospital colleague Yang Kan.

The girl had Snijders Blok-Campeau syndrome, a rare neurodevelopmental disorder with no effective treatment. After seeking help at several hospitals, her family approached Qiu, deputy director of the university medical school’s Songjiang Research Institute, in July 2023, hoping for a customized gene-editing therapy targeting the central nervous system.

Xinhua Hospital, which is affiliated with the medical school, approved the clinical study through its ethics committee on Jan. 2, 2025. The girl received an injection there on March 24, 2025, and died on March 31 despite resuscitation efforts.

At an emergency review on April 2, the ethics committee concluded that she had died of thrombotic microangiopathy, a complication of the gene therapy, and ordered the study stopped.

Investigators found that Qiu’s team had not promptly told the hospital’s clinical study leader about findings from a safety report on nonhuman primates, leaving its warning signals unheeded. The report had been completed in February 2025, the month before the injection.

The team also failed to promptly disclose the safety report and the girl’s death when it published its research in the journal Nature on Feb. 18. Investigators found no fabricated data in the paper but identified academic irregularities, including discrepancies between the methods used and those described.

The ethics committee approved the study despite insufficient toxicology and safety evidence, even though additional material it had requested had not been supplied. The consent form mentioned possible serious complications but did not prominently warn the family that she could die.

CT scans of a human brain. Illustation photo by Unsplash/U.S. National Cancer Institute

The family contributed 5.337 million yuan (US$800,000) to the research, most of it for viral vectors made by a company in Guangzhou and for safety tests on large animals by another in Sichuan.

Separately, researchers received about 1.06 million yuan ($159,000) in money and gifts from the family. Yang received 900,000 yuan and premium liquor, while Qiu received premium liquor and electronics worth about 100,000 yuan. The Shanghai’s investigation statement said all of it had been returned or handed over.

Two other team members, surnamed Zhang and Yuan, received 30,000 yuan each and were given administrative warnings. None of the four accurately disclosed conflicts of interest in the paper, investigators found.

The clinical study leader, surnamed Yu, was removed as head of Xinhua Hospital’s research department and demoted two grades. Hospital officials responsible for ethics review and research oversight were removed from their posts, demoted or given Communist Party disciplinary penalties.

District health authorities also penalized Xinhua Hospital and Songjiang District Central Hospital, and the city’s health commission has begun special inspections of clinical research involving new biomedical technologies.

The girl’s death came to light in July, when the journal Science reported that she had been the first person in the world to receive a gene-editing therapy directed at the brain, delivered by infusing viruses carrying the editor into her spinal fluid.

New Chinese rules that took effect in May limit investigator-initiated trials, which let doctors at test some novel therapies after local review, to top-tier hospitals, impose stricter manufacturing standards and toughen penalties for non-compliance.

Leave a Comment